BlackRock’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.53M Sell
5,138,022
-55,063
-1% -$104K ﹤0.01% 3724
2025
Q4
$12.4M Sell
5,193,085
-310,318
-6% -$849K ﹤0.01% 3366
2025
Q3
$15.7M Sell
5,503,403
-148,170
-3% -$507K ﹤0.01% 3237
2025
Q2
$21.3M Sell
5,651,573
-110,422
-2% -$434K ﹤0.01% 2983
2025
Q1
$26.1M Buy
5,761,995
+178,119
+3% +$943K ﹤0.01% 2781
2024
Q4
$39.5M Buy
5,583,876
+45,767
+0.8% +$364K ﹤0.01% 2608
2024
Q3
$45.1M Buy
5,538,109
+105,400
+2% +$762K ﹤0.01% 2530
2024
Q2
$34.7M Buy
5,432,709
+68,224
+1% +$438K ﹤0.01% 2640
2024
Q1
$40.4M Buy
5,364,485
+45,914
+0.9% +$419K ﹤0.01% 2569
2023
Q4
$49.2M Buy
5,318,571
+375,966
+8% +$3.07M ﹤0.01% 2482
2023
Q3
$50M Buy
4,942,605
+183,332
+4% +$2.19M ﹤0.01% 2393
2023
Q2
$59.5M Buy
4,759,273
+8,631
+0.2% +$103K ﹤0.01% 2383
2023
Q1
$55.4M Sell
4,750,642
-81,706
-2% -$1.04M ﹤0.01% 2373
2022
Q4
$51.4M Buy
4,832,348
+213,877
+5% +$2.06M ﹤0.01% 2443
2022
Q3
$44.8M Sell
4,618,471
-119,194
-3% -$1.58M ﹤0.01% 2523
2022
Q2
$68.6M Buy
4,737,665
+98,476
+2% +$1.68M ﹤0.01% 2272
2022
Q1
$121M Sell
4,639,189
-60,203
-1% -$1.71M ﹤0.01% 2014
2021
Q4
$186M Buy
4,699,392
+23,211
+0.5% +$1.06M ﹤0.01% 1785
2021
Q3
$234M Buy
4,676,181
+156,525
+3% +$8.54M 0.01% 1591
2021
Q2
$251M Buy
4,519,656
+1,991,894
+79% +$106M 0.01% 1602
2021
Q1
$118M Sell
2,527,762
-3,638
-0.1% -$176K ﹤0.01% 2095
2020
Q4
$110M Buy
2,531,400
+308,836
+14% +$11.4M ﹤0.01% 2030
2020
Q3
$81.3M Buy
2,222,564
+380,217
+21% +$12.9M ﹤0.01% 2014
2020
Q2
$53.7M Buy
1,842,347
+760,574
+70% +$21M ﹤0.01% 2213
2020
Q1
$28.3M Buy
1,081,773
+472,962
+78% +$14.5M ﹤0.01% 2417
2019
Q4
$21.1M Sell
608,811
-25,146
-4% -$832K ﹤0.01% 2848
2019
Q3
$20.1M Buy
+633,957
New +$25M ﹤0.01% 2822

Other funds holding HCAT

BlackRock's HCAT Position: Q1 2026 in Review

BlackRock reduced its Health Catalyst (HCAT) stake by 1.1% in Q1 2026, selling an estimated $104K and leaving 5,138,022 shares worth $6.53M. The position accounts for ﹤0.01% of the portfolio, ranked #3724.

BlackRock first reported a position in HCAT in Q3 2019 and has held it in 27 quarters since. The position peaked at $251M in Q2 2021. 130 funds tracked by Wall St. Rank hold HCAT as of Q1 2026.

  • BlackRock held 5,138,022 shares of Health Catalyst worth $6.53M as of Q1 2026.
  • BlackRock sold 55,063 Health Catalyst shares in Q1 2026, an estimated $104K.
  • Health Catalyst made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3724 holding.
  • BlackRock first reported a position in Health Catalyst in Q3 2019 and has held it in 27 quarters since.
  • BlackRock's Health Catalyst position peaked at $251M in Q2 2021.
  • 130 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.